Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.40 ▼ -0.01
(-1.34%)
MKT CAP: $90.8M • VOL: 1.78M
52W L $0 52W H $2
ROARABLE / RQD
D • 46/100
PIOTROSKI
3 / 9
TNYA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$93.3M | -$115.9M | -$131.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$90.6M | -$111.1M | -$124.1M |
| EBITDA (Normalized) | -$92.8M | -$115.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$68.3M | -$90.5M | -$102.1M |
| Capital Expenditures (CapEx) | $618.0K | $1.0M | — |
| Free Cash Flow (FCF) | -$68.9M | -$91.5M | -$102.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $100.5M | $4.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $123.3M | $92.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TNYA.